Last updated: September 1, 2026
Amlodipine besylate/olmesartan medoxomil is a mature fixed-dose antihypertensive combination marketed in the United States as Azor. Its commercial profile has shifted from branded innovation to generic volume. Revenue peaked before widespread generic competition, then declined as payer substitution, therapeutic interchange, and low-cost manufacturers compressed prices. The product remains commercially relevant because hypertension is chronic, treatment adherence benefits from combination dosing, and both ingredients have broad physician familiarity.
What is the market position of amlodipine besylate/olmesartan medoxomil?
Amlodipine besylate/olmesartan medoxomil combines a dihydropyridine calcium-channel blocker with an angiotensin II receptor blocker, or ARB.
| Attribute |
Product detail |
| Brand |
Azor |
| Active ingredients |
Amlodipine besylate and olmesartan medoxomil |
| Originator |
Daiichi Sankyo |
| FDA approval |
September 26, 2007 |
| Dosage strengths |
5/20 mg, 5/40 mg, 10/20 mg, and 10/40 mg |
| Therapeutic category |
Antihypertensive fixed-dose combination |
| FDA pathway |
New drug application, NDA 022100 |
| Primary market |
United States and other international hypertension markets |
| Current commercial status |
Generic small-molecule competition; no biosimilar pathway |
The product is indicated for patients whose blood pressure is not adequately controlled with monotherapy or as initial therapy in selected patients requiring more than one drug.[1]
The underlying market is large in patient volume but commoditized. Amlodipine is one of the most widely prescribed antihypertensive agents globally. Olmesartan has a smaller installed base than losartan, valsartan, or irbesartan, but it has retained demand through branded familiarity, generic availability, and combination products.
How does the product compare with competing antihypertensive combinations?
Amlodipine/olmesartan competes with both branded and generic fixed-dose combinations.
| Combination |
Commercial position |
Competitive effect |
| Amlodipine/olmesartan |
Azor and generics |
Differentiated by olmesartan efficacy perception and four strengths |
| Amlodipine/valsartan |
Exforge and generics |
Larger historical brand presence and broad generic penetration |
| Amlodipine/benazepril |
Lotrel and generics |
Established ACE inhibitor combination |
| Amlodipine/losartan |
Generic products |
Strong price competition |
| Amlodipine/telmisartan |
Twynsta and generics in some markets |
Competes in patients requiring long-acting ARB therapy |
| Olmesartan/hydrochlorothiazide |
Benicar HCT and generics |
Alternative olmesartan-based regimen |
| Olmesartan/amlodipine/hydrochlorothiazide |
Tribenzor and generics |
Captures patients requiring triple therapy |
The key commercial distinction is not molecule exclusivity. It is whether prescribers and payers value a single-tablet regimen enough to offset the availability of cheaper separate tablets. Generic amlodipine and generic olmesartan can often be prescribed separately at a lower acquisition cost than the fixed-dose combination.
When did Azor lose exclusivity?
Azor lost its practical branded exclusivity after the expiry of relevant small-molecule patent protection and the approval of abbreviated new drug applications. Generic competition has materially reduced the product's pricing power.
The market has passed through three phases:
- 2007 to approximately 2015: branded growth supported by fixed-dose convenience and Daiichi Sankyo promotion.
- Approximately 2016 to 2020: generic entry expanded, reducing branded prescription share and net price.
- 2021 onward: mature generic market with multiple suppliers, limited brand leverage, and reimbursement-driven substitution.
The exact launch timing varied by manufacturer and strength. FDA-approved generic products have been supplied by multiple companies, including major U.S. generic manufacturers and subsidiary platforms. The commercial result is the same: Azor no longer controls the category economically.
What patents protected amlodipine besylate/olmesartan medoxomil?
Azor's patent estate included composition and formulation protection associated with the combination of an ARB and a calcium-channel blocker, as well as patents covering olmesartan-related technology.
Historical U.S. Orange Book records associated with Azor included patents such as U.S. Patent Nos. 6,878,703 and 8,236,922, among other listings and related rights. Patent scope and expiration depended on the specific claim, terminal disclaimers, patent-term adjustment, and any pediatric extension.[2]
The original olmesartan product, Benicar, also relied on compound and formulation patents. Those rights protected the broader olmesartan franchise, but they did not prevent eventual generic competition for the active ingredient or for fixed-dose combinations.
What formulations were protected?
The commercial formulation consisted of immediate-release tablets containing:
- Amlodipine besylate at 5 mg or 10 mg
- Olmesartan medoxomil at 20 mg or 40 mg
- Four approved dose combinations
Formulation protection was more commercially important than manufacturing exclusivity after compound claims expired. Generic manufacturers could avoid infringement through alternative excipients, manufacturing processes, or claim interpretations, subject to ANDA certification and litigation risk.
What is the Orange Book status of Azor?
Azor is a listed prescription drug with historical Orange Book patent information and approved generic alternatives. The practical Orange Book risk has moved from patent blocking to product substitution.
A generic applicant must address listed patents through a Paragraph III certification, Paragraph IV certification, or other applicable certification. Paragraph IV litigation can delay approval for up to 30 months if the reference-product sponsor files suit within the statutory period.[3]
Because Azor is a small-molecule product with generic approvals, the principal market question is not whether generic entry is legally possible. It is how many manufacturers remain active, whether supply is reliable, and how aggressively pharmacy benefit managers and wholesalers negotiate pricing.
Which companies challenged Azor patents?
Generic companies that pursued amlodipine/olmesartan products included major ANDA sponsors such as Teva, Mylan, Torrent, and other manufacturers active in cardiovascular generics. The relevant challenges generally involved Paragraph IV certifications directed to listed combination or formulation patents.
Public litigation records for mature generic products can be fragmented across district court cases, appellate proceedings, consent judgments, and settlement agreements. The economic impact of these disputes was greatest before broad generic availability. Once several suppliers entered, later patent litigation had less ability to preserve substantial branded revenue.
What was the financial trajectory of the product?
Daiichi Sankyo does not consistently report Azor as a standalone global revenue line in its consolidated public financial statements. Product-specific U.S. net sales are therefore not available as a continuous, audited public series.
The financial trajectory can be assessed through commercial indicators:
| Period |
Revenue dynamic |
Main driver |
| 2007-2011 |
Expansion |
New combination, sales-force promotion, untreated combination-therapy demand |
| 2012-2015 |
Mature branded sales |
Physician familiarity and chronic refill volume |
| 2016-2020 |
Sharp erosion |
Generic entry, payer substitution, lower average selling price |
| 2021-present |
Low-price mature market |
Multiple generic suppliers and limited brand differentiation |
Branded revenue erosion typically occurs faster than prescription-volume erosion. Patients continue to require antihypertensive therapy, but the value shifts from the originator to generic manufacturers, wholesalers, pharmacies, and payers.
The product also lost revenue through therapeutic substitution. A prescriber can achieve similar blood-pressure control by prescribing separate amlodipine and olmesartan tablets, switching to another ARB combination, or using a triple therapy product.
What generic entry risks exist?
Generic entry risk is high and largely realized.
The main risks are:
- Direct substitution of generic amlodipine/olmesartan for Azor
- Substitution with separate generic tablets
- Formularies preferring amlodipine/valsartan, amlodipine/losartan, or other ARB combinations
- Pharmacy purchasing based on lowest-cost supplier
- Contracting pressure from Medicare Part D and commercial plans
- Limited patient willingness to pay for an originator brand after patent expiry
The remaining branded risks are usually limited to temporary supply disruptions, prescriber inertia, authorized-generic strategies, and narrow patient segments with established tolerance or adherence preferences.
Is there biosimilar risk for this product?
There is no biosimilar risk. Amlodipine besylate/olmesartan medoxomil is a chemically synthesized small-molecule combination, not a biologic.
The relevant competition is through ANDAs and generic substitution under the Hatch-Waxman framework. Bioequivalence, manufacturing quality, tablet strength, labeling, and supply continuity determine competitive performance.
How strong is the remaining patent estate?
The remaining commercial patent estate is weak relative to the original branded position.
| Patent-strength factor |
Assessment |
| Active-ingredient exclusivity |
Low; both active ingredients are generic |
| Fixed-dose combination protection |
Historically meaningful, but largely overcome |
| Formulation protection |
Narrow and vulnerable to design-around strategies |
| Method-of-use protection |
Limited economic value in a broad hypertension market |
| Manufacturing barriers |
Moderate operational complexity, low strategic exclusivity |
| Regulatory barrier |
Low for approved ANDA suppliers |
| Brand pricing power |
Low |
| Supply-chain value |
Moderate if a supplier maintains reliable inventory |
Manufacturing still matters. Olmesartan medoxomil and amlodipine tablets require validated blending, content uniformity, stability control, and reliable API sourcing. These factors can create temporary supply advantages, but they do not recreate patent exclusivity.
What patent litigation and settlement issues affect the market?
The important litigation period occurred before generic commercialization. Paragraph IV cases could determine whether a generic entered before the expiry of combination patents or after a negotiated date.
Settlement agreements in cardiovascular generics often included:
- A defined generic launch date
- No admission of patent validity or infringement
- Release of claims
- Possible authorized-generic arrangements
- Restrictions tied to specific strengths or formulations
The financial value of a settlement declined as additional manufacturers entered. A first-filer advantage can support a temporary price premium, but that premium normally compresses rapidly after multiple ANDAs become commercially active.
How does the U.S. market compare with international markets?
The United States has experienced the strongest generic price pressure because of ANDA competition, pharmacy benefit manager contracting, and substitution mechanisms. International markets differ.
In Japan, Europe, and emerging markets, commercial outcomes depend on:
- National reimbursement pricing
- Reference-pricing systems
- Local generic penetration
- Brand-prescribing norms
- Regulatory treatment of fixed-dose combinations
- Distribution and tender structures
Daiichi Sankyo's global portfolio has increasingly emphasized oncology and specialty medicines, including Enhertu, rather than mature cardiovascular brands. This portfolio shift reduces the strategic importance of Azor and related antihypertensive products in the company's long-term growth profile.[4]
What is the commercial outlook for amlodipine/olmesartan?
The product should be viewed as a stable, low-growth generic category rather than a growth pharmaceutical asset.
Volume demand should remain resilient because hypertension is chronic and treatment duration is long. Revenue growth is unlikely without a supply disruption, a new reimbursement advantage, or a differentiated adherence program. Generic manufacturers can generate acceptable returns through scale, efficient API procurement, and multi-product cardiovascular portfolios, but standalone investment returns are constrained by price competition.
The most attractive commercial opportunities are likely to involve:
- Reliable supply in shortage-prone markets
- Low-cost, high-volume manufacturing
- Regional registration and tender participation
- Combination-product portfolio expansion
- Contract manufacturing
- Patient adherence packaging
- Bundled distribution of cardiovascular generics
Key Takeaways
- Amlodipine/olmesartan is a mature fixed-dose antihypertensive combination marketed originally as Azor.
- FDA approval occurred in 2007, and the product is now subject to generic small-molecule competition.
- Brand revenue declined sharply after generic entry, while prescription demand remained relatively stable.
- The product has no biosimilar risk; ANDA-based generic competition is the relevant pathway.
- Patent protection historically covered the combination, formulation, and olmesartan technology, but the practical exclusivity barrier has been overcome.
- Separate generic amlodipine and olmesartan tablets are major substitutes for the fixed-dose product.
- Daiichi Sankyo's current strategic value is concentrated in newer specialty medicines, not mature antihypertensive brands.
- The post-exclusivity market offers volume and supply-chain opportunities, not meaningful branded pricing power.
FAQs
What is the brand name for amlodipine besylate and olmesartan medoxomil?
The U.S. brand name is Azor. It is available in 5/20 mg, 5/40 mg, 10/20 mg, and 10/40 mg strengths.
Is generic Azor available?
Yes. Generic amlodipine besylate/olmesartan medoxomil has been approved and commercialized by multiple manufacturers.
Is amlodipine/olmesartan more commercially attractive than amlodipine/valsartan?
Amlodipine/valsartan has historically had broader commercial recognition, but both products face substantial generic competition. Commercial attractiveness depends primarily on manufacturing cost, payer access, and supply reliability.
Can a generic manufacturer launch without infringing Azor patents?
A generic applicant must address applicable Orange Book patents through the appropriate ANDA certification. Launch timing depends on patent status, litigation, settlement terms, and FDA approval.
Does the combination have long-term revenue growth potential?
The category has durable patient demand but limited pricing growth. Revenue opportunities are concentrated in generic scale, regional expansion, supply reliability, and portfolio economics.
References
- U.S. Food and Drug Administration. (2007). Azor: Amlodipine besylate and olmesartan medoxomil prescribing information.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and Hatch-Waxman patent certification provisions.
- Daiichi Sankyo Co., Ltd. (2024). Annual report and integrated report.
